Abstract presentations have been announced for this year’s Gastrointestinal Cancers Symposium, which brings together clinicians and researchers from around the world to share the latest innovations in the treatment of gastrointestinal cancers. Learn about the latest research and multidisciplinary treatment strategies for GI malignancies by registering today.
Designed to maximize opportunities for podium presentation and research discussion, abstracts will be showcased in three Oral Abstract Sessions and Rapid Abstract Sessions. Daily Poster Sessions offer informal networking with attendees and researchers, as well as self-paced exploration of new research. Poster Walks, led by expert faculty, provide valuable opportunities for in-depth analysis of posters and research. The planning committee has selected a robust lineup of abstracts for presentation and a timely keynote lecture on immunotherapy. Topics for presentation and discussion include targeted molecular therapy, phase III studies on survival and safety, esophagectomy versus chemoradiotherapy, colorectal advancements with immunotherapy, and more.
Immunotherapy—Lessons Learned from Melanoma for Application to GI Malignancies featuring Siwen Hu-Lieskovan, MD, PhD
Oral Abstract Highlights in Esophagus and Stomach
Abstract 3: Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase 3 study (TAGS). First Author: David H. Ilson, MD, PhD
Abstract 7: Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502). First Author: Ken Kato, MD, PhD
Oral Abstract Highlights in Pancreas, Small Bowel and Hepatobiliary Tract
Abstract 186: Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase 3 study of lenvatinib (REFLECT). First Author: Masatoshi Kudo, MD, PhD
Abstract 188: Integrative molecular profiling and response to chemotherapy on the COMPASS trial. First Author: Grainne O’Kane, MB, BCh, BAO
Oral Abstract Highlights in Colon, Rectum and Anus
Abstract 480: A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results. First Author: Carl Christoph Schimanski, MD, PhD
Abstract 482: Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial. First Author: Charlotte Emma Louise Klaver, MD, BA
View the program for the full list of abstract titles, faculty, and session information. Don’t miss this opportunity to engage with colleagues and hear the latest updates. Register today and join AGA, ASCO, ASTRO and SSO in San Francisco for #GI9.